A retroviral mutagenesis screen reveals strong cooperation between Bc111a overexpression and loss of the Nf1 tumor suppressor gene

Blood

Volumn 113, Issue 5, 2009, Pages 1075-1085

  Yin, Bin ^a   Delwel, Ruud ^b   Valk, Peter J ^b   Wallace, Margaret R ^c   Loh, Mignon L ^d   Shannon, Kevin M ^d   Largaespada, David A ^a,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; NEUROFIBROMIN; BCL11A PROTEIN, HUMAN; BCL11A PROTEIN, MOUSE; CARRIER PROTEIN; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCL11A GENE; BONE MARROW; CARCINOGENICITY; CELL CULTURE; CELL LINEAGE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE INACTIVATION; GENE INSERTION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SCREENING; HEMATOPOIETIC CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOID CELL; MOUSE; MUTAGENESIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; CELL LINE; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOUSE MUTANT; RETROVIRUS; TRANSGENIC MOUSE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TRANSFORMED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTAGENESIS, INSERTIONAL; NEUROFIBROMIN 1; NUCLEAR PROTEINS; RETROVIRIDAE;

EID: 60849101342     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-144436     Document Type: Article

References (69)

1. Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004;17: 101-105.
2. Martin GA, Viskochil D, Bollag G, et al. The GAPrelated domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990; 63:843-849.
3. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69:265-273.
4. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356: 713-715.
5. Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP Ras. Proc Natl Acad Sci U S A. 1993;90:5539-5543.
6. Guo HF, The I, Hannan F, Bernards A, Zhong Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science. 1997;276:795-798.
7. Tong JJ, Schriner SE, McCleary D, Day BJ, Wallace DC. Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster. Nat Genet. 2007;39:476-485.
8. Xu H, Gutmann DH. Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res. 1997;759: 149-152.
9. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994;70:969-972.
10. Shannon KM, Le Beau MM, Largaespada DA, Killeen N. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. Semin Cancer Biol. 2001;11:191-200.
11. Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest. 2001;108:709-715.
12. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12:137-143.
13. Liu P, Keller JR, Ortiz M, et al. Bc111a is essential for normal lymphoid development. Nat Immunol. 2003;4:525-532.
14. Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001;98:3413-3420.
15. Weniger MA, Pulford K, Gesk S, et al. Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia. 2006;20:1880-1882.
16. Saiki Y, Yamazaki Y, Yoshida M, Katoh O, Nakamura T. Human EVI9, a homologue of the mouse myeloid leukemia gene, is expressed in the hematopoietic progenitors and down-regulated during myeloid differentiation of HL60 cells. Genomics. 2000;70:387-391.
17. Jenkins NA, Copeland NG, Taylor BA, Bedigian HG, Lee BK. Ecotropic murine leukemia virus DNA content of normal and lymphomatous tissues of BXH-2 recombinant inbred mice. J Virol. 1982;42:379-388.
18. Buchberg AM, Bedigian HG, Jenkins NA, Copeland NG. Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol Cell Biol. 1990;10:4658-4666.
19. Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol. 1995;69: 5095-5102.
20. Yin B, Kogan SC, Dickins RA, Lowe SW, Largaespada DA. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol. 2006;34: 631-641.
21. Yin B, Morgan K, Hasz DE, Mao Z, Largaespada DA. Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia. 2006;20: 151-154.
22. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994;8:1019-1029.
23. Zhu Y, Romero MI, Ghosh P, et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001;15:859-876.
24. Yin B, Largaespada DA. PCR-based procedures to isolate insertion sites of DNA elements. Biotechniques. 2007;43:79-84.
25. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389-3402.
26. Yin B, Tsai ML, Hasz DE, Rathe SK, Le Beau MM, Largaespada DA. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia. 2007;21: 1093-1097.
27. Sohal J, Phan VT, Chan PV, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood. 2003;101:3188-3197.
28. Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-633.
29. Blaydes SM, Kogan SC, Truong BT, et al. Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia. J Virol. 2001;75:9427-9434.
30. Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet. 1996;12:149-153.
31. Wakioka T, Sasaki A, Kato R, et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature. 2001;412:647-651.
32. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103: 4243-4250.
33. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
34. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99: 1474-1477.
35. Mitelman F, Johansson B, Mertens F (eds). Mitelman Database of Chromosome Aberrations in Cancer. http://cgapncinihgov/Chromosomes/ Mitelman. Accessed July 18, 2007.
36. Nakamura T, Yamazaki Y, Saiki Y, et al. Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell protooncogene product. Mol Cell Biol. 2000;20:3178-3186.
37. Kamimura K, Mishima Y, Obata M, Endo T, Aoyagi Y, Kominami R. Lack of Bc111b tumor suppressor results in vulnerability to DNA replication stress and damages. Oncogene. 2007;26:5840-5850.
38. Kamimura K, Ohi H, Kubota T, et al. Haploinsufficiency of Bc111b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun. 2007;355:538-542.
39. Hanlon L, Barr NI, Blyth K, et al. Long-range effects of retroviral insertion on c-myb: overexpression may be obscured by silencing during tumor growth in vitro. J Virol. 2003;77:1059-1068.
40. Weinberg RA. The Biology of Cancer. 1st ed. Oxford, United Kingdom: Garland Science; 2006.
41. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995;86:4603-4611.
42. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344:251-253.
43. Dedera DA, Waller EK, LeBrun DP, et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell. 1993;74:833-843.
44. Kamps MP, Baltimore D. E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell Biol. 1993;13:351-357.
45. King D, Yang G, Thompson MA, Hiebert SW. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype. Oncogene. 2002;21:4978-4982.
46. Gutmann DH, Winkeler E, Kabbarah O, et al. Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice. Oncogene. 2003;22:4581-4585.
47. de Ridder J, Kool J, Uren A, Bot J, Wessels L, Reinders M. Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes. Bioinformatics. 2007;23:133-141.
48. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer. 2005;4:323-333.
49. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593-602.
50. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683-695.
51. Yoon BI, Hirabayashi Y, Kawasaki Y, et al. Mechanism of action of benzene toxicity: cell cycle suppression in hemopoietic progenitor cells (CFUGM). Exp Hematol. 2001;29:278-285.
52. Steinman RA, Yaroslavskiy B, Kaplan SS, Goff JP, Shields DS. Clonal response of K562 leukemic cells to exogenous p21WAF1. Leuk Res. 2000;24:601-610.
53. Baccini V, Roy L, Vitrat N, et al. Role of p21(Cip1/ Waf1) in cell-cycle exit of endomitotic megakaryocytes. Blood. 2001;98:3274-3282.
54. Albanese P, Chagraoui J, Charon M, et al. Forced expression of p21 in GPIIb-p21 transgenic mice induces abnormalities in the proliferation of erythroid and megakaryocyte progenitors and primitive hematopoietic cells. Exp Hematol. 2002;30: 1263-1272.
55. Alcantara O, Boldt DH. Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1/CIP1). Br J Haematol. 2007;137:252-261.
56. Shen S, Passioura T, Symonds G, Dolnikov A. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation. Exp Hematol. 2007;35: 908-919.
57. Mantel C, Luo Z, Canfield J, Braun S, Deng C, Broxmeyer HE. Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo. Blood. 1996;88:3710-3719.
58. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell quiescence maintained by p21cip1/ waf1. Science. 2000;287:1804-1808.
59. Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood. 2007;109:4392-4398.
60. Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 2002;21:8486-8497.
61. Wei W, Jobling WA, Chen W, Hahn WC, Sedivy JM. Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol. 2003;23:2859-2870.
62. Oskarsson T, Essers MA, Dubois N, et al. Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev. 2006;20:2024-2029.
63. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6:663-673.
64. Senawong T, Peterson VJ, Leid M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch Biochem Biophys. 2005;434:316-325.
65. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137-148.
66. Khalaf WF, Yang FC, Chen S, et al. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/-mast cells. J Immunol. 2007;178:2527-2534.
67. Kim A, Morgan K, Hasz DE, et al. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 2007;109: 1687-1691.
68. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinalcentre B cells. Nature. 2004;432:635-639.
69. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/ p53-induced cellular senescence. EMBO J. 2002; 21:2383-2396.